Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
103.09
-0.18 (-0.17%)
At close: Nov 20, 2024, 4:00 PM
102.87
-0.22 (-0.21%)
Pre-market: Nov 21, 2024, 5:42 AM EST
Novartis AG Employees
Novartis AG had 76,057 employees as of December 31, 2023. The number of employees decreased by 25,646 or -25.22% compared to the previous year.
Employees
76,057
Change (1Y)
-25,646
Growth (1Y)
-25.22%
Revenue / Employee
$656,613
Profits / Employee
$231,445
Market Cap
205.45B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
Dec 31, 2019 | 103,914 | -21,247 | -16.98% |
Dec 31, 2018 | 125,161 | 3,564 | 2.93% |
Dec 31, 2017 | 121,597 | 3,204 | 2.71% |
Dec 31, 2016 | 118,393 | -307 | -0.26% |
Dec 31, 2015 | 118,700 | -14,713 | -11.03% |
Dec 31, 2014 | 133,413 | -2,283 | -1.68% |
Dec 31, 2013 | 135,696 | 7,972 | 6.24% |
Dec 31, 2012 | 127,724 | 4,038 | 3.26% |
Dec 31, 2011 | 123,686 | 4,268 | 3.57% |
Dec 31, 2010 | 119,418 | 19,584 | 19.62% |
Dec 31, 2009 | 99,834 | 3,117 | 3.22% |
Dec 31, 2008 | 96,717 | -1,483 | -1.51% |
Dec 31, 2007 | 98,200 | -2,535 | -2.52% |
Dec 31, 2006 | 100,735 | 9,735 | 10.70% |
Dec 31, 2005 | 91,000 | 9,600 | 11.79% |
Dec 31, 2004 | 81,400 | 2,859 | 3.64% |
Dec 31, 2003 | 78,541 | 5,664 | 7.77% |
Dec 31, 2002 | 72,877 | 2,557 | 3.64% |
Dec 31, 2001 | 70,320 | 1,252 | 1.81% |
Dec 31, 2000 | 69,068 | -13,391 | -16.24% |
Dec 31, 1999 | 82,459 | -3,376 | -3.93% |
Dec 31, 1998 | 85,835 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
Danaher | 63,000 |
NVS News
- 5 hours ago - Novartis: launch of Morphosys drug by could be 2027 or later - Reuters
- 6 hours ago - Novartis Lifts Sales Outlook on Key Drugs, Pipeline Portfolio - WSJ
- 7 hours ago - Novartis raises annual sales guidance until 2028 - Reuters
- 7 hours ago - Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth - GlobeNewsWire
- 2 days ago - Novartis ranks first in 2024 Access to Medicine Index - GlobeNewsWire
- 3 days ago - Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate - PRNewsWire
- 9 days ago - Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer - Business Wire
- 9 days ago - Schrödinger's stock pops as it enters collaboration pact with Novartis worth up to $2.5 billion - Market Watch